Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China; Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, 100191, China; Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China.
Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China.
Pharmacol Res. 2019 Sep;147:104386. doi: 10.1016/j.phrs.2019.104386. Epub 2019 Aug 1.
Coronary heart disease remains a major threaten for public health worldwide, and pharmacological or mechanical coronary reperfusion are currently used for treatment of acute coronary syndrome. However, restoration of blood flow to ischemic myocardium leads to ischemia/reperfusion (I/R) injury. Microcirculatory disturbance and cardiac injury after I/R occur via a complex pathologic process including metabolism impairment in the ischemia phase and oxidative stress in the reperfusion phase. Obviously, any treatment targeting a single link is insufficient to cope with I/R injury. Investigation in the past decade in our laboratory as well as in other's demonstrated the cardioprotection potential of QiShenYiQi Pills (QSYQ) and ingredients in experimental animal models of I/R injury. These results have offered insight into the mechanism thereby QSYQ prevents against cardiac I/R injury in clinic. This review will outline the results with respect to the effect of QSYQ and major bioactive ingredients on I/R-induced microcirculatory disturbance, cardiac injury and fibrosis, with emphasis on the underlying mechanisms.
冠心病仍然是全球公共卫生的主要威胁，目前临床上常采用药理学或机械的方法来实现冠状动脉再灌注以治疗急性冠脉综合征。然而，恢复缺血心肌的血流会导致缺血/再灌注（I/R）损伤。I/R 后微循环障碍和心脏损伤是通过一个复杂的病理过程发生的，包括缺血期的代谢损伤和再灌注期的氧化应激。显然，针对单一环节的任何治疗都不足以应对 I/R 损伤。过去十年我们实验室及其他实验室的研究表明，芪参益气滴丸（QSYQ）及其成分在 I/R 损伤的实验动物模型中具有心脏保护作用。这些结果为其预防临床心脏 I/R 损伤的机制提供了新的认识。本综述将概述 QSYQ 和主要生物活性成分对 I/R 诱导的微循环障碍、心脏损伤和纤维化的影响，并重点介绍其潜在机制。
